A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects
Latest Information Update: 23 Dec 2021
At a glance
- Drugs Anumigilimab (Primary)
- Indications Hidradenitis suppurativa; Inflammation; Palmoplantar pustulosis; Rheumatoid arthritis
- Focus Pharmacokinetics
- Acronyms CSL324_1003
- Sponsors CSL Behring
- 17 Dec 2021 Status changed from recruiting to completed.
- 29 Sep 2021 Planned End Date changed from 1 Oct 2021 to 1 Nov 2021.
- 29 Sep 2021 Planned primary completion date changed from 1 Oct 2021 to 1 Nov 2021.